SCHEMBL4842528

SCHEMBL4842528

Fc1ccc(Oc2cc(NCCN3CCOCC3)c3c(-c4ccccc4Cl)n[nH]c3n2)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
CYP1A2 P05177 6/20 0.42
CYP3A4 P08684 6/20 0.42
CYP2D6 P10635 5/20 0.42
CYP2C19 P33261 4/20 0.42
CLK4 Q9HAZ1 4/20 0.42
HSD17B10 Q99714 4/20 0.42
TSHR P16473 3/20 0.42
ALOX15 P16050 2/20 0.42
KDM4E B2RXH2 3/20 0.41
HIF1A Q16665 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MAPK14 Q16539 1/20 0.40
LMNA P02545 3/20 0.40
USP2 O75604 2/20 0.39
MAPK1 P28482 1/20 0.39
CCNT1 O60563 1/20 0.38
HPGD P15428 2/20 0.38
BCL3 P20749 1/20 0.37
CSF1R P07333 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4836395 0.87 CYP1A2 (0.44) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4832587 0.86 CYP1A2 (0.44) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4841046 0.82 SMN1; SMN2 (0.42) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4021094 0.82 MAPK14 (0.33) MAPK14LMNABRD4
SCHEMBL4844936 0.80 MAPK14 (0.41) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL13769733 0.79 MAPK14 (0.40) ALDH1A1KDM4ENPSR1MAPK14MAPK1
SCHEMBL4837424 0.79 EGFR (0.41) KDM4EMAPK14BRD4
SCHEMBL4015293 0.79 MAPK14 (0.35) MAPK14LMNA
SCHEMBL4015286 0.79 MAPK14 (0.35) MAPK14LMNA
SCHEMBL4833357 0.77 MAPK14 (0.36) MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7435731-B2 Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same ROCHE PALO ALTO LLC (US) 2008-10-14 US disclosed
US-7435731-B2 Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same ROCHE PALO ALTO LLC (US) 2008-10-14 US disclosed
US-7435731-B2 Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same ROCHE PALO ALTO LLC (US) 2008-10-14 US disclosed
US-20050197340-A1 Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same ROCHE PALO ALTO LLC 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197340-A1 Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same MAP3K1, MAPK1, MAP3K8 ALDH1A1 2715/4885CYP1A2 982/4885CYP3A4 1980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.